Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hypertension and the kidney]

E Ritz1

  • 1Medizinische Universitätsklinik, Sektion Nephrologie, Heidelberg.

Arzneimittel-Forschung
|February 14, 1998
PubMed
Summary
This summary is machine-generated.

Hypertension accelerates kidney disease progression, contrary to past beliefs. Lowering blood pressure and using ACE inhibitors or calcium channel blockers are key for kidney protection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De novo glomerulonephritis in patients during remission from Wegener's granulomatosis.

Clinical nephrology·1992
Same author

Reduced capillary density in the myocardium of uremic rats--a stereological study.

Kidney international·1992
Same author

Renal histology in polycystic kidney disease with incipient and advanced renal failure.

Kidney international·1992
Same author

The effect of uninephrectomy on progression of renal failure in autosomal dominant polycystic kidney disease.

Journal of the American Society of Nephrology : JASN·1992
Same author

Severe hemorrhagic complications from infection with nephropathia epidemica strain of Hantavirus.

Clinical nephrology·1992
Same author

Disturbed calcium metabolism in renal failure--pathogenesis and therapeutic strategies.

Kidney international. Supplement·1992
Same journal

Wirksamkeit und Verträglichkeit eines pflanzlichen Arzneimittels mit Kapuzinerkressenkraut und Meerrettich bei akuter Sinusitis, akuter Bronchitis und akuter Blasenentzündung im Vergleich zu anderen Therapien unter den Bedingungen der täglichen Praxis.

Arzneimittel-Forschung·2013
Same journal

Abstracts of the Paul-Martini-Stiftung Symposium 2012 in combination with the National Academy of Leopoldina. November 16-17, 2012. Berlin, Germany.

Arzneimittel-Forschung·2013
Same journal

Leave-one-out procedure in the validation of elimination rate constant analysis.

Arzneimittel-Forschung·2012
Same journal

Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.

Arzneimittel-Forschung·2012
Same journal

Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer.

Arzneimittel-Forschung·2012
Same journal

Effect of zeolite nano-materials and artichoke (Cynara scolymus L.) leaf extract on increase in urinary clearance of systematically absorbed nicotine.

Arzneimittel-Forschung·2012
See all related articles

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Pharmacology

Context:

  • The understanding of hypertension's role in chronic kidney disease (CKD) has evolved significantly over 30 years.
  • Previously, elevated blood pressure was thought to aid kidney function in damaged kidneys.
  • Current evidence highlights hypertension as a primary driver of renal function decline.

Purpose:

  • To summarize the paradigm shift in understanding the relationship between hypertension and kidney disease progression.
  • To highlight the evolution of therapeutic targets for blood pressure management in renal disease.
  • To review the comparative efficacy of antihypertensive agents in preserving renal function.

Summary:

  • Blood pressure is now recognized as the most critical factor accelerating progressive loss of renal function.

Related Experiment Videos

  • Therapeutic target blood pressure levels in hypertensive patients with kidney disease have been substantially lowered.
  • Angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers demonstrate superior nephroprotective effects compared to other antihypertensive agents.

    • Impact:

    • This shift in understanding necessitates revised clinical guidelines for managing hypertension in patients with kidney disease.
    • Lowering blood pressure targets and utilizing specific antihypertensive classes can significantly slow CKD progression.
    • The findings underscore the importance of nephroprotection in comprehensive renal disease management.